Quick Heal Technologies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹65 Cr −22.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
QH

Quick Heal Technologies Ltd

Q4 FY25IT - Software

Quick Heal Technologies Q4 FY25: Revenue ₹65.1 Cr, PAT ₹3.3 Cr

Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹65Cr
−18.6% YoY
−7.7% QoQ
Net profit
−₹3Cr
Q4 FY24: ₹14 Cr
Margin
−13.02%
−25.6 pp YoY
−7.7 pp QoQ

Quick Heal Technologies Ltd Q4 FY25 key numbers

Revenue
FY25 Revenue: ₹279.5 Cr, down from ₹291.8 Cr in FY24 (-4.2% YoY).

As stated in Quick Heal Technologies Ltd's Q4 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Quick Heal Technologies Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹148
Market cap₹827 Cr

The short version

Q4 FY25 Revenue: ₹65.1 Cr, down from ₹80.0 Cr in Q4 FY24 (approx. Q4 FY25 EBITDA: -₹8.5 Cr (down from ₹10.0 Cr in Q4 FY24) - Q4 FY25 EBITDA Margin: -13.0% (down from 12.6% in Q4 FY24) - Q4 FY25 Profit After Tax (PAT): -₹3.3 Cr (down from ₹14.0 Cr in Q4 FY24) - Q4 FY25 PAT Margin: -5.0% (down from 17.5% in Q4 FY24) Year-on-Year changes indicate a significant decline in profitability and margins compared to the same quarter previous year.

From Quick Heal Technologies Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q4 FY25 Revenue: ₹65.1 Cr, down from ₹80.0 Cr in Q4 FY24 (approx. -18.6% YoY) (Page 31)
  • FY25 Revenue: ₹279.5 Cr, down from ₹291.8 Cr in FY24 (-4.2% YoY) (Page 24, 31)
  • Consumer Revenue FY25: ₹185.7 Cr, down 9.2% YoY (Page 25, 24)

2 more points from Quick Heal Technologies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Quick Heal Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Capital work-in-progress decreased from ₹3.1 Cr (Mar 31, 2024) to ₹0.1 Cr (Mar 31, 2025), indicating minimal ongoing capital projects. - Property, plant & equipment values remained stable (₹83.6 Cr to ₹83.2 Cr). No direct references to capex plans, capacity expansions, or new plant/project launches with amounts or timelines are found in the provided content.

Top-ranked in IT - Software

Ranked on what management guided this quarter

Guidance-ranked
1Workmates Core2
Rev 1Mar 1
2Virtual Galaxy
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Quick Heal Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Order Book: INR 24+ Cr as on date (Page 20, Business Highlights)
  • New Product Billing: FY25 > 3x FY24 (Page 20)
  • Deferred Revenue: INR 12+ Cr (Page 20)
  • First order for Seqrite Threat Intelligence received (Page 20)

Quick Heal Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Quick Heal Technologies Ltd Q4 FY25 results — key figures

Quick Heal Technologies Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue6580-18.6%71-7.7%
Operating profit (EBITDA)-810-184.5%-4—
Operating margin-13.02%12.55%-25.6 pp-5.34%-7.7 pp
Profit before tax-714-148.5%-2—
Net profit (PAT)-314-123.1%0-3054.5%
EPS (₹)-0.602.62-122.9%0.02-3100%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹65 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in IT - Software this season

  • ASM Technologies (Q4 FY25)

    Q4 FY24: ₹445.92 million . Key concall takeaways from ASM Technologies Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Olatech Solution (Q4 FY25)

    Current order book in hand: ₹35 crores (as of June 2025). Key concall takeaways from Olatech Solutions Ltd's Q4 FY25 earnings call — and how it ranks against…

  • Birlasoft Ltd (Q4 FY25)

    The company has a strong cash position with cash and cash equivalents growing 24% YoY to $259.5 million as of FY25 end. Key concall takeaways from Birlasoft…

  • Wipro (Q4 FY25)

    FY25 experienced a 2.3% decline in IT Services revenue (constant currency); Q4 saw a sequential decline of 0.8%. Key concall takeaways from Wipro Ltd's Q4 FY25…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Quick Heal Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Quick Heal Technologies Ltd Q4 FY25 results?

Q4 FY25 Revenue: ₹65.1 Cr, down from ₹80.0 Cr in Q4 FY24 (approx. Q4 FY25 EBITDA: -₹8.5 Cr (down from ₹10.0 Cr in Q4 FY24) - Q4 FY25 EBITDA Margin: -13.0% (down from 12.6% in Q4 FY24) - Q4 FY25 Profit After Tax (PAT): -₹3.3 Cr (down from ₹14.0 Cr in Q4 FY24) - Q4 FY25 PAT Margin: -5.0% (down from 17.5% in Q4 FY24) Year-on-Year changes indicate a significant decline in profitability and margins compared to the same quarter previous year.

What is Quick Heal Technologies Ltd share price analysis?

Quick Heal Technologies Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹827 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Quick Heal Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.